EL
ELVN.US Enliven Therapeutics Inc.
- Market cap
- USD 3.59B
- P/E
- -
- P/B
- 4.05x
- ROE
- -12.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ELVN.US undervalued?
Graham numberThe Graham number of Enliven Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Enliven Therapeutics Inc. fundamental analysis
No fundamental analysis for Enliven Therapeutics Inc. yet.
Enliven Therapeutics Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Enliven Therapeutics Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical…
Full company profileEnliven Therapeutics Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Enliven Therapeutics Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | -33.0K | -97.0K | -99.0K | -622K | -297K | -317K | -263K | - |
| Operating Income | -8.91M | -10.7M | -24.1M | -9.32M | -24.8M | -38.8M | -83.5M | -105M | -120M | -135M |
| EBITDA | 221K | -11.3M | -23.4M | -9.27M | -24.6M | -37.4M | -71.3M | -88.5M | -103M | -112M |
| Net Income | - | -11.3M | -23.5M | -19.0M | -24.7M | -37.7M | -71.6M | -89.0M | -104M | -112M |
| EPS | - | -2.62 | -5.43 | -4.32 | -3.17 | -6.03 | -2.01 | -1.89 | -1.83 | -1.43 |
| Balance Sheet | ||||||||||
| Total Assets | 10.2M | 7.71M | 33.3M | 90.8M | 113M | 83.3M | 272M | 326M | 476M | 897M |
| Total Liabilities | 1.49M | 1.83M | 4.38M | 6.41M | 6.47M | 160M | 26.0M | 15.9M | 16.6M | 20.3M |
| Shareholders' Equity | -15.5M | -26.3M | -48.8M | 84.4M | 107M | -76.8M | 246M | 310M | 460M | 877M |
| Cash & Short-term Investments | 9.67M | 7.38M | 28.9M | 88.2M | 110M | 75.5M | 253M | 313M | 463M | 884M |
| Total Debt | 660K | - | - | 105K | 159K | 323K | 335K | - | 399K | 1.32M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -8.79M | -8.78M | -21.9M | -8.53M | -19.1M | -32.1M | -61.3M | -73.2M | -70.3M | -67.2M |
| Capital Expenditure | 0.00 | 0.00 | 140K | 461K | 191K | 612K | 149K | 44.0K | 158K | 257K |
| Free Cash Flow | -8.79M | -8.78M | -22.0M | -8.99M | -19.3M | -32.7M | -61.4M | -73.2M | -70.5M | -67.4M |
| Ratios | ||||||||||
| ROE | - | - | - | -22.5% | -23.2% | - | -29.1% | -28.7% | -22.6% | -12.7% |
| ROA | - | -147.1% | -70.5% | -20.9% | -21.8% | -45.2% | -26.3% | -27.3% | -21.8% | -12.5% |
| Debt to Equity | - | - | - | 0.00x | 0.00x | - | 0.00x | - | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Enliven Therapeutics Inc. dividends
Enliven Therapeutics Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:4 on Feb 24, 2023.
Who owns Enliven Therapeutics Inc.
- Insiders 6.19%
- Institutions 93.81%
- Public & others 0.00%
- Shares outstanding 73.6M
- Free float 60.8M
Top funds holding ELVN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Polar Capital Healthcare Opports Inc | 3.61M | 4.91% | 0.00% | Sep 2026 |
| Polar Capital Biotech S Inc | 2.56M | 3.47% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.11M | 2.86% | +11.55% | Sep 2026 |
| Fidelity Small Cap Growth | 1.52M | 2.06% | 0.00% | Aug 2026 |
| iShares Russell 2000 ETF | 1.48M | 2.01% | 0.00% | Oct 2026 |
| Fidelity Select Health Care | 1.28M | 1.74% | -4.48% | Aug 2026 |
| Strategic Advisers Fidelity US TtlStk | 1.12M | 1.53% | +52.29% | Sep 2026 |
| Pictet-Biotech P USD | 865K | 1.18% | +12.86% | Jul 2026 |
| Fidelity Stock Selector Small Cap | 825K | 1.12% | +17.79% | Aug 2026 |
| Fidelity Small Cap Growth K6 | 749K | 1.02% | 0.00% | Aug 2026 |
| Fidelity Advisor Health Care I | 630K | 0.86% | 0.00% | Sep 2026 |
| Fidelity Select Biotechnology | 619K | 0.84% | +48.27% | Aug 2026 |
| T. Rowe Price New Horizons | 609K | 0.83% | -14.32% | Sep 2026 |
| Fidelity Advisor Biotechnology I | 575K | 0.78% | +14.60% | Sep 2026 |
| Fidelity Series Small Cap Opps | 550K | 0.75% | +8.11% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 546K | 0.74% | -0.38% | Oct 2026 |
| Candriam Eqs L Biotech C USD Cap | 479K | 0.65% | -2.88% | Apr 2026 |
| iShares Biotechnology ETF | 473K | 0.64% | -0.19% | Oct 2026 |
| Fidelity Small Cap Index | 469K | 0.64% | +0.14% | Aug 2026 |
| American Century Small Cap Growth Inv | 428K | 0.58% | 0.00% | Sep 2026 |
Top institutions holding ELVN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 10.0M | 13.62% | +46.80% | Jun 2026 |
| Orbimed Advisors LLC | 6.78M | 9.21% | -14.86% | Jun 2026 |
| Polar Capital Holdings PLC | 6.43M | 8.74% | +26.94% | Jun 2026 |
| BlackRock Inc | 4.36M | 5.92% | +18.32% | Jun 2026 |
| Vestal Point Capital LP | 4.00M | 5.44% | +23.08% | Jun 2026 |
| COMMODORE CAPITAL LP | 3.28M | 4.45% | 0.00% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 2.90M | 3.95% | +2,870.84% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.57M | 3.49% | +18.49% | Jun 2026 |
| Citadel Advisors Llc | 2.07M | 2.81% | +18.64% | Jun 2026 |
| Fairmount Funds Management LLC | 1.86M | 2.52% | 0.00% | Jun 2026 |
| Siren, L.L.C. | 1.77M | 2.41% | +137.78% | Jun 2026 |
| Bellevue Group AG | 1.49M | 2.02% | -35.80% | Jun 2026 |
| Geode Capital Management, LLC | 1.41M | 1.91% | +31.96% | Jun 2026 |
| First Light Asset Management, LLC | 1.36M | 1.85% | +574.08% | Jun 2026 |
| State Street Corp | 1.21M | 1.65% | +11.23% | Jun 2026 |
| Pictet Asset Manangement SA | 1.16M | 1.58% | +24.98% | Jun 2026 |
| Adage Capital Partners Gp LLC | 1.08M | 1.47% | 0.00% | Jun 2026 |
| Novo A/S | 1.00M | 1.36% | -21.88% | Jun 2026 |
| First Turn Management LLC | 954K | 1.30% | +52.98% | Jun 2026 |
| Samlyn Capital, LLC | 913K | 1.24% | 0.00% | Jun 2026 |
Enliven Therapeutics Inc. company profile
- Company name
- Enliven Therapeutics Inc.
- Ticker
- ELVN.US
- Exchange
- USA Stocks
- Listed since
- Mar 12, 2020
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 65
- Fiscal year end
- December
- Address
- 205 Park Road, Burlingame, CA, United States, 94010
- Phone
- (650) 547-5814
- Website
- enliventherapeutics.com
About Enliven Therapeutics Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is based in Burlingame, California.
Enliven Therapeutics Inc. management
8- Mr. Richard A. Fair M.B.A.CEO, President & Director · born 1969
- Mr. Samuel S. Kintz M.B.A.Co-Founder & Head of Pipeline · born 1986
- Mr. Benjamin HohlCFO & Head of Corporate Development · born 1989
- Dr. Helen Louise Collins M.D.Chief Medical Officer · born 1963
- Dr. Joseph P. Lyssikatos Ph.D.Co-Founder & Research Fellow · born 1965
- Mr. Anish Patel Pharm.D.Co-Founder & COO · born 1981
- Dr. Galya D. Blachman Esq., Ph.D.Chief Legal Officer & Head of Business Development · born 1977
- Damiette SmitVice President of Clinical Development